UBS Group
CEREW

UBS Group’s Cerevel Therapeutics Holdings, Inc. Warrant CEREW Stock Holding History

UBS Group’s Portfolio CEREW Stock Details CEREW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-538
Closed -$2K – 10257
2021
Q1 		$2K Hold
538
– – ﹤0.01% 8715
2020
Q4 		$3K Buy
+538
New +$2.17K ﹤0.01% 8058

Other funds holding CEREW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS Group's CEREW Position: Q2 2021 in Review

UBS Group sold out of Cerevel Therapeutics Holdings, Inc. Warrant (CEREW) in Q2 2021, closing a stake of 538 shares — an estimated $2K sold.

UBS Group first reported a position in CEREW in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q4 2020. 22 funds tracked by Wall St. Rank hold CEREW as of Q2 2021.

  • UBS Group reported no remaining Cerevel Therapeutics Holdings, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • UBS Group sold 538 Cerevel Therapeutics Holdings, Inc. Warrant shares in Q2 2021, an estimated $2K.
  • UBS Group first reported a position in Cerevel Therapeutics Holdings, Inc. Warrant in Q4 2020 and held it in 2 quarters.
  • UBS Group's Cerevel Therapeutics Holdings, Inc. Warrant position peaked at $3K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Warrant as of Q2 2021.

Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.